AIM Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 mai 2024 @ 21:57):

Stats
Dagens volum	116 604
Gjennomsnittsvolum	236 640
Markedsverdi	20.17M
EPS	$0 ( 2024-04-02 )
Neste inntjeningsdato	( $-0.120 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.670
ATR14	$0.00600 (1.48%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-30	Rodino Peter W Iii	Buy	100 000	Options
2023-11-30	Equels Thomas K	Buy	300 000	Options
2024-03-21	Bryan Nancy	Buy	38 462	Common Stock
2024-03-15	Appelrouth Stewart	Buy	90 910	Common Stock
2024-03-15	Equels Thomas K	Buy	75 758	Common Stock

INSIDER POWER
89.44
Last 98 transactions
Buy: 4 006 121 \| Sell: 118 208

Volum Korrelasjon

Lang: -0.11 (neutral)

Kort: -0.17 (neutral)

Signal:(53.983) Neutral

AIM ImmunoTech Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

AIM ImmunoTech Inc Korrelasjon - Valuta/Råvare

0.53
( weak )

0.51
( weak )

0.00
( neutral )

0.09
( neutral )

AIM ImmunoTech Inc Økonomi

Annual	2023
Omsetning:	$202 000
Bruttogevinst:	$-78 000.00 (-38.61 %)
EPS:	$-0.600

FY	2023
Omsetning:	$202 000
Bruttogevinst:	$-78 000.00 (-38.61 %)
EPS:	$-0.600

FY	2022
Omsetning:	$141 000
Bruttogevinst:	$-19.78M (-14 029.79 %)
EPS:	$-0.440

FY	2021
Omsetning:	$135 000
Bruttogevinst:	$-715 000 (-529.63 %)
EPS:	$-0.400

Financial Reports:

No articles found.

AIM ImmunoTech Inc

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.